Want to see JP:4893 full AI Analyst Report?

Noile-Immune Biotech Inc. (4893) Price & Analysis

0 Followers

4893 Stock Chart & Stats

¥134.00

¥9.00(4.81%)

At close: Jan 08 4:00 PM EST

¥134.00

¥9.00(4.81%)

Day’s Range― - ―

52-Week Range¥114.00 - ¥217.00

Previous CloseN/A

Volume1.93M

Average Volume (3M)85.17K

Market Cap

¥6.02B

Enterprise Value¥1.54B

Total Cash (Recent Filing)¥3.74B

Total Debt (Recent Filing)¥0.00

Price to Earnings (P/E)―

Beta1.41

Next Earnings

Aug 13, 2026

EPS Estimate

-5.51

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-16.31

Shares Outstanding43,276,764

10 Day Avg. Volume110,290

30 Day Avg. Volume85,173

Financial Highlights & Ratios

PEG Ratio0.41

Price to Book (P/B)1.46

Price to Sales (P/S)1151.82

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-18.33

Revenue Forecast (FY)¥300.00M

Bulls Say, Bears Say

Bulls Say

No Debt / Conservative Balance SheetA zero-debt capital structure meaningfully reduces solvency and interest-rate risk over the next several months. With no leverage, management has more flexibility to raise equity or prioritize R&D investments while avoiding fixed financing costs that could accelerate distress if revenues stay weak.

Very High Gross MarginsNear-100% gross margins indicate strong per-unit economics for its cell-therapy products and suggest scalability once revenue growth resumes. Durable gross profit potential gives the company a structural path to profitability if it can control operating expenses and commercialize clinical assets.

Clinical-stage Cell Therapy PipelineA portfolio spanning preclinical and clinical-stage cell-based immunotherapies positions the company within a long-term growth segment of oncology. Clinical assets and proprietary NK engineering provide potential milestone and partnership value that can materially change fundamentals over a 2–6 month horizon if programs progress.

Bears Say

Sharp, Sustained Revenue DeclineMaterial revenue contraction undermines the company's ability to leverage high gross margins into operating profitability. Continued top-line shrinkage reduces runway, weakens commercial traction, and makes it harder to justify ongoing R&D spend without additional financing or strategic partnerships.

Persistent Negative Operating Cash FlowChronic operating cash outflows force reliance on external funding and increase dilution risk. Even with improved burn in 2025, sustained negative free cash flow constrains investment optionality, pressures the equity base, and elevates execution risk for clinical programs absent new capital.

Deep Net Losses And Negative ROESevere net losses and persistently negative ROE indicate shareholder capital is not generating returns and is being eroded by operations. This structural unprofitability limits self-funding capacity, raises probability of equity raises, and complicates long-term planning for commercialization and scaling.

4893 FAQ

What was Noile-Immune Biotech Inc.’s price range in the past 12 months?

Noile-Immune Biotech Inc. lowest stock price was ¥114.00 and its highest was ¥217.00 in the past 12 months.

What is Noile-Immune Biotech Inc.’s market cap?

Noile-Immune Biotech Inc.’s market cap is ¥6.02B.

When is Noile-Immune Biotech Inc.’s upcoming earnings report date?

Noile-Immune Biotech Inc.’s upcoming earnings report date is Aug 13, 2026 which is in 10 days.

How were Noile-Immune Biotech Inc.’s earnings last quarter?

Noile-Immune Biotech Inc. released its earnings results on May 14, 2026. The company reported -¥3.54 earnings per share for the quarter, beating the consensus estimate of -¥5.05 by ¥1.51.

Is Noile-Immune Biotech Inc. overvalued?

According to Wall Street analysts Noile-Immune Biotech Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Noile-Immune Biotech Inc. pay dividends?

Noile-Immune Biotech Inc. does not currently pay dividends.

What is Noile-Immune Biotech Inc.’s EPS estimate?

Noile-Immune Biotech Inc.’s EPS estimate is -5.51.

How many shares outstanding does Noile-Immune Biotech Inc. have?

Noile-Immune Biotech Inc. has 43,276,764 shares outstanding.

What happened to Noile-Immune Biotech Inc.’s price movement after its last earnings report?

Noile-Immune Biotech Inc. reported an EPS of -¥3.54 in its last earnings report, beating expectations of -¥5.05. Following the earnings report the stock price went down -3.356%.

Which hedge fund is a major shareholder of Noile-Immune Biotech Inc.?

Currently, no hedge funds are holding shares in JP:4893

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Noile-Immune Biotech Inc.

Established in 2015 and based in Minato, Japan, this company is dedicated to exploring and advancing CAR-T cell technology for use in cancer immunotherapy treatments.